Balanced news tone
News Sentiment
RZLT sentiment intelligence
Rezolute Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
49 relevant articles
News tone and price action are not far from neutral.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-3.3% over one week, +18.8% over four weeks, trend active, and near fair-value range.
Form 4 Rezolute Inc For: 7 July By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
75/100 classification
One-week reaction
-3.3%
Price reacting lower
Trend fit
Trend active
18.8% over four weeks
Fair value
21.7%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
30
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Direct company coverage
Rezolute’s stock up on interim Phase III tumour HI data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- Market source
MT Newswires
Direct company coverage
Update: Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 18:16
- Source
- MT Newswires
MT Newswires
Direct company coverage
Rezolute Says 6 Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 12:25
- Source
- MT Newswires
Seeking Alpha
Direct company coverage
Rezolute rises after late-stage trial update (RZLT:NASDAQ)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Seeking Alpha
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Opaleye-affiliated holders report 6.3M shares in Rezolute (RZLT)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Stock Titan
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Seeking Alpha
Direct company coverage
Rezolute gains after positive FDA meeting over lead asset
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 24 Mar 2026 07:00
- Source
- Seeking Alpha
simplywall.st
Direct company coverage
Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 16 Feb 2026 08:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Rezolute (RZLT) Valuation Revisited After Phase 3 sunRIZE Trial Misses Primary and Key Secondary Endpoints
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 25 Dec 2025 08:00
- Source
- simplywall.st
PR Newswire
Direct company coverage
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Dec 2025 08:00
- Source
- PR Newswire
Market source
Direct company coverage
Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Dec 2025 08:00
- Source
- Market source
Market source
Direct company coverage
Rezolute (RZLT) Is Down 82.7% After Phase 3 sunRIZE Failure in Congenital Hyperinsulinism Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Dec 2025 08:00
- Source
- Market source
Hagens Berman
Direct company coverage
Rezolute, Inc. (RZLT) Investigation
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 11 Dec 2025 08:00
- Source
- Hagens Berman